Established in 1995, MacroMed is a specialty biopharmaceutical company focused on developing and commercializing innovative pharmaceutical products utilizing its proprietary polymer technologies. MacroMed collaborates with major pharmaceutical and biotechnology companies and has its own pipeline of several products in various stages of preclinical and clinical development for cancer management (OncoGel®, Cytoryn), moderate to moderately severe pain (Dolotyn) and growth hormone deficiency (Ascentra).